---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-071211"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-06-08T13:01:47+00:00"
generated_at: "2026-06-08T13:03:32.633608+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MetaVia DA-1726 48mg cohort achieves 9.1% weight loss at Day 54; vanoglipel combo shows synergy in MASH/T2D

## Summary
- DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.
- Waist circumference reduced by 9.8 cm at Day 54; BMI reduced by 3.4 kg/m².
- Vanoglipel + resmetirom in MASH mouse model: 23.6% weight loss vs control, ALT reduction 83.5%.
- Vanoglipel + metformin in T2D model: 16.3% weight loss, 28.7% non-fasting glucose reduction.
- Phase 1 Part 3 titration studies for higher-dose DA-1726 ongoing; results expected Q4 2026.

## SEC filing metadata
- accession: 0001104659-26-071211
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-06-08T13:01:47+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/0001104659-26-071211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/mtva-20260608x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-071211
- JSON: https://secwatch.observer/filing/0001104659-26-071211.json
- Plain text: https://secwatch.observer/filing/0001104659-26-071211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.